RBX
Genentech sold GDC0084 with a licence agreement in 2016
Genentech has not had to worry about ongoing expenditure for2016, 2017,2018,2019 etc
Genentech has received an upfront payment of $5m plus other entitlements - milestone payments as per licence agreement
Genentech does not need worry about upwards of $20m for phase 11b trial and imo will receive a milestone payment if phase 11b commences
Genentech does not need to hit the market for capital for GDC0084
DYOR all above fair and realistic debating points
- Forums
- ASX - By Stock
- KZA
- Value of Cantrixil
Value of Cantrixil, page-9
-
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)